The $100M milestone adds substantial near-term cash for a sub-$700M market cap company, reducing financing risk. Key catalysts ahead: ASRS data in July and pivotal ATMOSPHERE/ASCENT topline data in Q4 2026. Monitor for sustained momentum on sura-vec across diabetic retinopathy and wet AMD indications.
Price Chart
Executive Summary
REGENXBIO announced the first patient dosing in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec) in diabetic retinopathy using suprachoroidal delivery. This triggered a $100 million milestone payment from AbbVie, expected in July 2026. The event de-risks the program's regulatory path and provides a significant non-dilutive cash infusion for a company with a $677 million market cap.
Key Facts
- First patient dosed in Phase IIb/III NAAVIGATE trial of surabgene lomparvovec in diabetic retinopathy (suprachoroidal delivery)
- $100 million milestone payment earned from AbbVie, expected in July 2026
- NAAVIGATE trial to enroll approximately 135 participants in the US; primary endpoint is >2-step DRSS improvement at one year
- Two-and-a-half year data from ALTITUDE trial and five-year data from Phase I/IIa subretinal wet AMD study to be presented at ASRS July 2026
- Topline data from ATMOSPHERE and ASCENT pivotal trials of subretinal sura-vec in wet AMD expected in Q4 2026
Financial Impact
$100 million near-term cash milestone from AbbVie, representing ~15% of current market cap
Risk Factors
- Phase IIb/III trial may fail to meet primary endpoint of >2-step DRSS improvement
- Competition from existing anti-VEGF therapies and emerging gene therapies for retinal diseases
- Dependence on AbbVie partnership for commercialization and further milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-286825 |
| Document: 0001193125-26-286825-index.html | 0001193125-26-286825 |
| Document: 0001193125-26-286825.txt | 0001193125-26-286825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access